5AM Partners Liquidates Skye Bioscience Stake After 14.65% Weekly Surge, Insiders Shift Risk Exposure
5AM Partners’ insider sell‑off of Skye Bioscience highlights short‑term risk‑rebalancing amid a 90% year‑to‑date drop; monitor upcoming clinical milestones for potential upside.
3 minutes to read
